PCI Biotech: Successful completion of the first group in the intra-tumour light dose escalation part of the ENHANCE study

Oslo, 24 January 2014 - PCI Biotech (PCIB) the Norwegian biopharmaceutical
company, reported today that the treatment evaluation of the first group in the
intra-tumour light dose escalation part of the ENHANCE study has been
completed.  ENHANCE is a phase II study of Amphinex® in combination with the
cytotoxic agent bleomycin in recurrent head and neck cancer patients. No safety
concerns were raised and a clear but insufficient tumour response was seen at
this light dose level.

The first level of the light dose escalating part of the trial is now completed.
A Dose Review Committee (DRC) of clinical experts and company representatives
has been established to evaluate the results and provide recommendation for the
continuation of the study. The DRC has recommended that the light dose is
escalated according to the protocol. Patients for the next light dose level are
currently being screened and will be treated with Amphinex® as soon as possible.

About PCI Biotech
PCI Biotech is a Norwegian biopharmaceutical company developing a novel light
directed treatment system based on its patented photochemical internalisation
(PCI) technology. Originating from world leading research at the Norwegian
Radium Hospital, the PCI method involves first injecting the photosensitiser
Amphinex® and thereafter the therapeutic drug to be specifically delivered to
the diseased cells. When the diseased cells are illuminated the cells' endosomes
are ruptured to allow successful intracellular delivery of the drug.

PCI can enhance the delivery of all molecules taken into the cell by
endocytosis. This includes most types of macromolecules, drugs carried by
antibodies or nanoparticles, as well as some small molecule drugs.

The PCI technology is also a versatile and innovative vaccination platform,
which may specifically increase the cytotoxic T-cell response of vaccines. This
is particularly important in therapeutic vaccination, when the immune system
needs to recognise and destroy diseased cells (e.g. virus infected cells and
cancer).

PCI Biotech follows a strategy to create value by improving the effect both of
existing cancer drugs and by realizing the large potential in new therapeutics,
including therapeutic vaccines.

For more information visit: www.pcibiotech.com


Contact information:
PCI Biotech Holding ASA, Strandveien 55, N-1366 Lysaker
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 940 05 757

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.


[HUG#1756934]